ReviewCancers2020
Evolution of the Experimental Models of Cholangiocarcinoma.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.Nature reviews. Gastroenterology & hepatology · 2023Guideline
- Liver organoids: From fabrication to application in liver diseases.Frontiers in physiology · 2022Pooled it
- How to efficiently establish animal models of cholangiocarcinoma: challenges and inspiration.Medical review (2021) · 2026Review
- Establishment and characterization of CHC-X1: the third human combined hepatocellular-cholangiocarcinoma cell line.BMC cancer · 2025Article
- Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids.Journal of translational medicine · 2025Review
- Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre-clinical models.Clinical & translational immunology · 2025Review
- Applications of 3D models in cholangiocarcinoma.Frontiers in oncology · 2025Review
- Establishment and characterization of a new intestinal-type ampullary carcinoma cell line, DPC-X3.BMC cancer · 2024Article
- Establishment and characterization of a novel human gallbladder cancer cell line, GBC-X1.Scientific reports · 2024Article
- Establishment and characterization of the PDAC-X3 cell line: a novel Chinese-origin pancreatic ductal adenocarcinoma cell line.Human cell · 2024Article
- Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1.BMC cancer · 2024Article
- A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma.Scientific reports · 2024Article
- Radiographic features predictive of recurrence and survival after surgical resection of perihilar cholangiocarcinoma.Heliyon · 2024Article
- Establishment and characterization of DPC-X4: a novel mixed-type ampullary cancer cell line.Human cell · 2024Article
- Article
- Advances, challenges and future applications of liver organoids in experimental regenerative medicine.Frontiers in medicine · 2024Review
- Porcine-human glioma xenograft model. Immunosuppression and model reproducibility.Cancer treatment and research communications · 2024Article
- [Treatment of Ampullary Adenocarcinoma].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players.Pathogens (Basel, Switzerland) · 2023Review
- Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma.JHEP reports : innovation in hepatology · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is a rare, aggressive disease with poor overall survival. In advanced cases, surgery is often not possible or fails; in addition, there is a lack of effective and specific therapies. Multidisciplinary approaches and advanced technologies have improved the knowledge of CCA molecular pathogenesis, highlighting its extreme heterogeneity and high frequency of genetic and molecular aberrations. Effective preclinical models, therefore, should be based on a comparable level of complexity. In the past years, there has been a consistent increase in the number of available CCA models. The exploitation of even more complex CCA models is rising. Examples are the use of CRISPR/Cas9 or stabilized organoids for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.